Exploring New Frontiers in Addiction Treatment: CASPR-Funded Study at the CMC VAMC & PREF

We are thrilled to announce an innovative study funded by the Center for Addiction Science and Policy Research (CASPR) in partnership with the Philadelphia Research and Education Foundation (PREF). This groundbreaking research at the Corporal Michael J. Crescenz VA Medical Center investigates the potential of GLP-1 receptor agonists - medications typically used to manage diabetes and obesity - in reducing opioid overdose rates and addressing opioid use disorder (OUD) among veterans. 

The VA's distinctive healthcare infrastructure, characterized by stable, long-term patient relationships, offers an exceptional platform for examining complex health outcomes like OUD. The study is spearheaded by Dr. Dave Oslin, Director of VISN 4 Mental Illness Research, Education and Clinical Center (MIRECC) and Core Investigator at the Center for Health Equity Research and Promotion (CHERP). It involves a retrospective analysis of patient health records to assess the effects of GLP-1 medications on veterans with a history of OUD. 

“GLP-1 receptor agonists have garnered significant attention for their roles in weight loss and diabetes management. Emerging evidence suggests these medications might also aid in reducing substance misuse. If validated, their clinical application could become a vital tool in combating the morbidity and mortality associated with addiction,” Dr. Oslin stated. 

Preliminary findings indicate that GLP-1 receptor agonists may inadvertently diminish cravings not only for food but also for substances such as alcohol and opioids. This study aims to further validate these promising observations within a veteran population, potentially leading to a significant reduction in opioid overdoses. A decrease of 40-50% in overdose rates could transform treatment approaches and offer renewed hope for veterans struggling with addiction. 

This study marks the beginning of what we hope will be a series of collaborative efforts between CASPR and the VA. We extend our heartfelt gratitude to CASPR's donors and funders who make such transformative research possible!